Merck Plans Lantus Follow-On This Year, Releases Phase III Data At ADA
This article was originally published in The Pink Sheet Daily
Merck released positive Phase III data on its follow-on biologic, insulin glargine, for diabetes at the American Diabetes Association Scientific Sessions, positioning the insulin category for fierce pricing competition.
You may also be interested in...
Samsung Bioepis will be responsible for development, manufacturing and registration, while Merck will be responsible for commercializing any resulting drugs. Merck says the partnership will complement the firm’s internal biologics portfolio.
In the midst of another restructuring, the company is transitioning from a drug discovery company to a more externally focused R&D model; CEO Jackie Fouse talked to Scrip about the changes at Agios.
Chief medical officer Roger Dansey has stepped in as interim CEO until a new one is appointed.